Medical/Pharmaceuticals
Biotechnology Start-Up Psylo Wins Hello Tomorrow APAC Deep Tech Competition in Singapore
SINGAPORE, Oct. 31, 2023 /PRNewswire/ -- Psylo, a biotechnology start-up pioneering the development of next-generation serotonergic agents for the treatment of central nervous system (CNS) disorders, today announced that it won the Hello Tomorrow APAC deep tech competition held inSingapore. The ...
iNtRON, Executes Evaluation License and Option Agreement for SAL200
* iNtRON Grants Basilea exclusive right for preclinical evaluation with an undisclosed payment * Basilea has the option to enter into exclusive License Agreement following the evaluation BOSTON and SEOUL, South Korea, Oct. 30, 2023 /PRNewswire/ -- iNtRON Biotechnology ("iNtRON",www.intodeworl...
CStone Announces NMPA Approval of Sugemalimab for Patients with Relapsed or Refractory Extranodal NK/T-cell Lymphoma, the First Anti-PD-1/PD-L1 mAb Approved for this Indication
* Sugemalimab is the world's first anti-PD-1/PD-L1 monoclonal antibody approved for relapsed or refractory extranodal NK/T-cell lymphoma (R/R ENKTL) indication. * This marks sugemalimab's third indication approved in China following Stage III and IV non-small cell lung cancer (NSCLC) and the ...
AffaMed Therapeutics Announced Positive Top-Line Results from Real-World Study in China Evaluating the Safety and Efficacy of DEXTENZA® in Patients after Cataract Surgery
SHANGHAI, Oct. 31, 2023 /PRNewswire/ -- AffaMed Therapeutics ("AffaMed"), a global biotechnology company dedicated to developing and commercializing transformative pharmaceutical, digital and surgical products that address critical unmet medical needs in ophthalmological, neurological and psychia...
SK Life Science Labs, a Subsidiary of SK Biopharmaceuticals, Presents Discovery of Oral SMARCA2 Degraders Data at 6th Annual Targeted Protein Degradation Summit
Preclinical data show SK Life Science Labs compounds have robust anti-tumor efficacy in vivo and oral leads have demonstrated potent selective degradation of SMARCA2 with selective inhibition of proliferation of SMARCA4 mutant cells KING OF PRUSSIA, Pa., Oct. 31, 2023 /PRNewswire/ -- SK Life Scie...
Bridge Biotherapeutics Announces Initiation of Phase 1/2 Clinical Trial of BBT-207 in EGFR-Mutant NSCLC
SEONGNAM, South Korea and NEWTON, Mass., Oct. 30, 2023 /PRNewswire/ -- Bridge Biotherapeutics (KQ288330), a South Korean clinical-stage biotech company developing novel drugs for cancer, fibrosis, and inflammation, announced that the company has initiated the Phase 1/2 clinical trial evaluating t...
LifeSpan Vision Ventures Invests in NaNotics
NORWALK, Conn., Oct. 31, 2023 /PRNewswire/ -- LifeSpan Vision Ventures, an investment firm dedicated to longevity biotech, today announced an investment in NaNotics LLC. This preclinical-stage biopharmaceutical company is developing NaNots™, novel subtractive nanoparticles that treat disease by c...
Pulsecare Medical's nsPFA clinical trial receives satisfactory short-term follow-up results
SHENZHEN, China, Oct. 30, 2023 /PRNewswire/ -- Pulsecare Medical, an innovative minimally invasive and non-invasive therapeutic technology company, announced today that its nanosecond pulsed field ablation (nsPFA) system for cardiac electrophysiology, the world's first third-generation pulsed fie...
AIRS Medical Accelerates Global Expansion, Showcasing clinical achievements of MRI Enhancement Solution at RSNA 2023
* Recently achieved MDSAP certification and ISO/IEC 27001, 27017, 27018 certifications, paving the way for accelerated expansion into global markets. * Certified Japan's Pharmaceuticals and Medical Devices Agency (PMDA), signaling the beginning of its full-scale expansion into the Japanese mar...
NCCN Expands Focus on Quality of Life and Supportive Care with New Guides for People with Cancer
National Comprehensive Cancer Network publishes free NCCN Guidelines for Patients with information on improving well-being and reducing suffering and distress for people with cancer; available atNCCN.org/patientguidelines. PLYMOUTH MEETING, Pa., Oct. 30, 2023 /PRNewswire/ -- The National Compreh...
WuXi AppTec Continued Solid Growth in the First Three Quarters of 2023 on Top of an Exceptionally Strong Year in 2022, with Profit Growth Continuously Exceeding Revenue Growth
* Revenue of RMB10,670 Million in the Third Quarter, Single Quarter Revenue Back to overRMB10 Billion; Revenue of RMB29,541 Million in the First Three Quarters, Up 4.0% Year-over-Year; Excluding COVID-19 Commercial Projects, Up 23.4% * Net Profit Attributable to Owners of the Company for the ...
Journal of Thoracic Oncology Published Promising Results of Ivonescimab (PD-1/VEGF Bispecific) as First- or Second-line Therapy for Advanced or Metastatic Immunotherapy Naïve Non-Small-Cell Lung Cancer
HONG KONG, Oct. 30, 2023 /PRNewswire/ -- Akeso (9926.HK) announced that the results of a phase Ib clinical trial for PD-1/VEGF bispecific antibody ( ivonecimab AK112/SMT112 ) as first- or second-line therapy for advanced or metastatic immunotherapy naïve non-small-cell lung cancer (NSCLC) were p...
New Clinical Data Point to Use of GlycoMark as Biomarker of SGLT-2 Diabetes Drug Effectiveness and Compliance
RALEIGH, N.C., Oct. 30, 2023 /PRNewswire/ -- Precision Diabetes, Inc. announces new studies that show that the GlycoMark blood test, which measures 1,5-anhydroglucitol, may be useful for evaluating short-term effectiveness and assessing patient compliance of SGLT-2 inhibitor diabetes drugs. SGLT-...
Rational Vaccines and Shenzhen Mellow Hope Pharm Industrial Co., Ltd. Announce Collaboration to Develop Herpes Vaccines in China
The partnership will further therapeutic and prophylactic vaccine development for the Chinese market and beyond. WOBURN, Ma. and SHENZHEN, China, Oct. 30, 2023 /PRNewswire/ -- Rational Vaccines (RVx) and Shenzhen Mellow Hope Pharm Industrial Co., Ltd. (MH) announced they have reached an agreemen...
Aquinnah Pharmaceuticals Advances Oral Small Molecule Program Targeting Alzheimer's and Other Tauopathy Diseases
New preclinical data presented at CTAD demonstrates exciting potential for a new drug approach for Alzheimer's disease, reducing brain tau pathology by ~70% CAMBRIDGE, Mass., Oct. 30, 2023 /PRNewswire/ -- Aquinnah Pharmaceuticals announced preclinical research findings for a novel therapeutic des...
Foresee Pharmaceuticals to Present at the American Heart Association Annual Meeting Focusing on its ALDH2 activator FP-045 in Pulmonary Hypertension Associated with Interstitial Lung Disease
TAIPEI, Oct. 30, 2023 /PRNewswire/ -- Foresee Pharmaceuticals (TPEx: 6576), ("Foresee") announced today that the company will be presenting at the American Heart Association (AHA) 2023 Annual Meeting taking place inPhiladelphia, PA, fromNovember 11-13, 2023. The presentation will focus on Foresee...
First Patient Enrolled in Phase III Clinical Trial of Boan Biotech's Nivolumab Injection
YANTAI, China, Oct. 30, 2023 /PRNewswire/ -- Boan Biotech (6955.HK) announced today that the first patient in Phase III clinical trial of its Nivolumab Injection (BA1104) inChina has been enrolled. BA1104 is the first biosimilar to Opdivo® to undergo a Phase III study in China. Nivolumab is a mo...
Alltech Joins Vital Group to Build an Industry Chain for High-End Medical Imaging
CHENGDU, China, Oct. 30, 2023 /PRNewswire/ -- On Oct. 28th, Alltech, a high-end medical imaging equipment developer under the umbrella of Vital Group, held a press conference titled "Joy of Life, Dream of Innovation" at the 88th China International Medical Equipment Fair (CMEF), where it announce...
Linq Wins Samsung Open Collaboration with LLM-Enhanced Underwriting AI Solution
SEOUL, South Korea, Oct. 30, 2023 /PRNewswire/ -- Linq, an AI startup, won first place in the 2023 Samsung Open Collaboration, one of the most prestigious startup competitions inSouth Korea. Linq showcased its AI-powered underwriting solution, which was made possible by its AI risk models and an ...
Innovent Announces Robust Weight Loss Efficacy, Multiple Metabolic Benefits and Favorable Safety Profile of Higher Dose 9 mg Mazdutide (IBI362) after 48-week Treatment in Phase 2 Study for Obesity
* Mazdutide demonstrates its differentiated advantages as a novel dual agonist of GLP-1 and GCG receptor with superior weight loss efficacy, significant improvement in a series of cardiometabolic indicators (waist circumference, blood pressure, liver enzyme, triglyceride, low-density lipoprote...
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 314 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30QDX Co-Founder Giuseppe Barca Awarded Prestigious Gordon Bell Prize, Pioneering Advancements in Drug Discovery Technology
[Picked up by 293 media titles]
2024-11-26 18:49Southeast Asian Consumers Raise Online Security Concerns, New GSMA Survey Shows
[Picked up by 290 media titles]
2024-11-26 13:00